Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 106.72M P/E - EPS this Y 45.50% Ern Qtrly Grth -
Income -71.89M Forward P/E -1.38 EPS next Y 11.80% 50D Avg Chg -7.00%
Sales 24.52M PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 0.94 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.70 Quick Ratio 2.03 Shares Outstanding 71.95M 52W Low Chg 14.00%
Insider Own 12.13% ROA -18.78% Shares Float 33.22M Beta 3.13
Inst Own 18.83% ROE -71.28% Shares Shorted/Prior 672.77K/679.27K Price 1.92
Gross Margin 94.86% Profit Margin - Avg. Volume 61,158 Target Price 7.43
Oper. Margin -1,257.30% Earnings Date - Volume 48,619 Change -4.48%
About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A. News
04/22/24 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
04/10/24 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
04/08/24 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
04/04/24 Monthly information on share capital and company voting rights
01/16/24 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
12/22/23 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
11/17/23 Cellectis’ Shareholders Meeting to be Held on December 22, 2023
11/15/23 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
11/08/23 Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript
11/06/23 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
11/02/23 Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
11/01/23 Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
11/01/23 Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
10/31/23 Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
10/24/23 Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
10/12/23 Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
10/03/23 These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird
09/27/23 Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
08/07/23 Cellectis Provides Full Report for Second Quarter 2023 Financial Results
08/03/23 Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
CLLS Chatroom

User Image Stock_Titan Posted - 3 days ago

$CLLS Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs https://www.stocktitan.net/news/CLLS/cellectis-presents-novel-talen-r-editing-processes-enabling-highly-hwpt5ssqxuk7.html

User Image DonCorleone77 Posted - 2 weeks ago

$CLLS Cellectis publishes new research paper in Molecular Therapy Cellectis announced the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells, or HSPCs, enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain. The CD11b intron-specific gene insertion approach efficiently restricts the expression of a desired transgene to the myeloid lineage, preventing its overexpression by stem cells or by other differentiated lineages. The insertion of an IDUA transgene in the first intron of the CD11b gene enables to express IDUA (the enzyme missing in Mucopolysaccharidosis type I patients), in a myeloid-specific manner without affecting CD11b endogenous expression....

User Image Stock_Titan Posted - 2 weeks ago

$CLLS Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs https://www.stocktitan.net/news/CLLS/cellectis-publishes-a-novel-intronic-gene-editing-approach-for-the-efqasx5qaabx.html

User Image Stock_Titan Posted - 2 weeks ago

$CLLS Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting https://www.stocktitan.net/news/CLLS/cellectis-announces-two-poster-presentations-on-novel-talen-r-i1n4txwv0iyt.html

User Image Stock_Titan Posted - 3 weeks ago

$CLLS Monthly information on share capital and company voting rights https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-wlji5gfi0en5.html

User Image Doozio Posted - 3 weeks ago

$CLLS 30 bucks in 2021. Huckleberries are fresh in 🧠⏰♾️. Gotta be at least a move to 6.69?

User Image grinchspan Posted - 3 weeks ago

@ben1501 $clls. Yes ... call it a preview to the end state of this company.

User Image Newyorkerr Posted - 03/29/24

$CLLS https://www.pharmaceutical-technology.com/analyst-comment/io360-first-allogeneic-dual-car-t-shows-promise-in-b-cell-non-hodgkin-lymphoma/?cf-view

User Image chris6611 Posted - 1 month ago

$CLLS Dividend!

User Image trump4ever2016 Posted - 1 month ago

$AKBA $DARE $CLLS $HEPA $CLRB

User Image jacksparo Posted - 1 month ago

$HEPA $CLLS $DARE $CLRB $AKBA I'll thoroughly evaluate multiple biotech stocks this weekend, as several catalysts are expected to occur between March and April. Stay tuned for updates via email, as I'll identify strong performers!

User Image Samuelp1239 Posted - 1 month ago

$CLLS finally hit support lol

User Image Stock_Titan Posted - 1 month ago

$CLLS Monthly information on share capital and company voting rights https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-vwy3hxzfafct.html

User Image 4Reel Posted - 02/28/24

$CLLS remember cash runway to 2026 thanks to Astrazeneca. Astrazeneca also paid $5 per share and for the preferred shares $140M is at $5. Not sure why they got the second tranch of 15m Euros though when they are so highly liquid. Need to see some support

User Image ben1501 Posted - 2 months ago

$CLLS is this chat room dead? What do we see in the future ⬆️or ⬇️

User Image grinchspan Posted - 01/27/24

$CLLS 3 months to 2.2

User Image Samuelp1239 Posted - 3 months ago

$CLLS 🤑🤑🤑

User Image grinchspan Posted - 3 months ago

$CLLS why do you buy this stock. Because you want to watch your money circle the drain with the rudderless company.

User Image Ulong Posted - 3 months ago

$CLLS "Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)" Read more: https://www.cellectis.com/en/press/cellectis-announces-the-drawndown-of-the-second-tranche-of-15-million-under-the-credit-facility-agreement-entered-with-the-european-investment-bank-eib

User Image cctranscripts Posted - 3 months ago

Report of foreign issuer [Rules 13a-16 and 15d-16] https://www.conferencecalltranscripts.org/summary/?id=12869767 $CLLS

User Image Samuelp1239 Posted - 3 months ago

$CLLS so what’s not to like abt this stock? Everything looks good… is it bc it’s not popular/no volume?

User Image STCKPRO Posted - 3 months ago

$CLLS NEW ARTICLE : Cellectis SA: A Hold Rating Amidst Strategic Partnerships and Pipeline Potential https://www.stck.pro/news/CLLS/72548440/

User Image tickeron Posted - 3 months ago

How does this make you feel? $CLLS price exceeded its 50-day Moving Average. View odds of downtrend. https://srnk.us/go/4967221

User Image Stock_Titan Posted - 3 months ago

$CLLS Monthly information on share capital and company voting rights https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-8dj0ykaifl08.html

User Image Samuelp1239 Posted - 3 months ago

$CLLS why???

User Image luciferr92 Posted - 3 months ago

$CLLS anyone here?

User Image frenchflair Posted - 3 months ago

$CLLS salut mes petits ricains adorés Allogène publie une mise au point sur le futur des CAR-T https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-2024-platform-vision-redefine bisous french

User Image StockAutomatePro Posted - 3 months ago

$CLLS Chart is suggesting a bearish outlook for the stock. We alerted the SELL signal at $3.52 and we were able to close this one with profit at $2.961 😎 See more details at StockAutomate.com

User Image DrBullmoney Posted - 3 months ago

$BETSF ready to rocket! Dont forget to join the short squeeze! Dont miss it! $PWM $SXTC $LMDX $CLLS

User Image DrBullmoney Posted - 3 months ago

$BETSF join the short squeeze, shorts trapped and ready to get burned. 1$ gap up fill target. Do t miss this opportunity. $CLLS $IDICQ $GMDAQ $CDIO

Analyst Ratings
JMP Securities Market Outperform Nov 1, 23
Oppenheimer Outperform Aug 8, 23
JMP Securities Market Outperform Aug 7, 23
Citigroup Buy Apr 5, 23
Oppenheimer Outperform Mar 13, 23
JMP Securities Market Outperform Mar 13, 23
JMP Securities Market Outperform Jan 19, 23
Goldman Sachs Sell May 24, 22
Baird Outperform May 18, 22